Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
15.73
-0.23 (-1.44%)
Aug 7, 2025, 4:00 PM - Market closed
Immunovant Employees
Immunovant had 362 employees as of March 31, 2025. The number of employees increased by 155 or 74.88% compared to the previous year.
Employees
362
Change (1Y)
155
Growth (1Y)
74.88%
Revenue / Employee
n/a
Profits / Employee
-$1,143,204
Market Cap
2.69B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 362 | 155 | 74.88% |
| Mar 31, 2024 | 207 | 43 | 26.22% |
| Mar 31, 2023 | 164 | 40 | 32.26% |
| Mar 31, 2022 | 124 | 56 | 82.35% |
| Mar 31, 2021 | 68 | 26 | 61.90% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMVT News
- 2 months ago - Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 - GlobeNewsWire
- 5 months ago - Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward - Seeking Alpha
- 5 months ago - Immunovant's muscle disorder treatment meets main goal in late-stage trial - Reuters
- 5 months ago - Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies - GlobeNewsWire
- 5 months ago - Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - GlobeNewsWire
- 6 months ago - Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - GlobeNewsWire
- 6 months ago - Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PRNewsWire
- 7 months ago - Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study - Seeking Alpha